Revance Therapeutics (RVNC) Misses Q4 EPS by $1.08

Revance Therapeutics (NASDAQ: RVNC) reported Q4 EPS of ($1.82), $1.08 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $49.9 million versus the consensus estimate of $44.91 million.

For earnings history and earnings-related data on Revance Therapeutics (RVNC) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Interactive Strength reports record Q2 results, raises Q3 guidance
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance